UBS Maintains Buy on Amgen, Raises Price Target to $470

Benzinga Newsdesk www.benzinga.com Positive 79.4%

Neg 0% Neu 0% Pos 79.4%

UBS analyst Michael Yee maintains Amgen (NASDAQ:AMGN) with a Buy and raises the price target from $430 to $470.

Comments

No comments yet. Be the first!